California's Hub and Spoke System Learning Collaborative 3

Talking to Patients about MAT

Gloria Miele, Ph.D., Learning Collaborative Coordinator UCLA Integrated Substance Abuse Programs (ISAP)

Mark McGovern, Ph.D. Stanford University

Feb 23, Mar 5, Mar 9, Mar 22, 2018

Agenda

- ► Welcome, introductions
- Using patient-centered language
- ► Talking to patients about MAT TTC
- ► Practice presentation Matrix
- Ol reporting and PDSA
- ► Action planning what's next, upcoming events, resources

Talking to patients about substance use

Reducing stigma

The use of affirming language inspires hope and advances recovery.

LANGUAGE MATTERS. Words have power. PEOPLE FIRST.

The ATTC Network uses affirming language to promote the promises of recovery by advancing evidence-based and culturally informed practices.



Language and Stigma

No other medical condition is shrouded in stigma like that of substance use disorders. This harmful stigma affects those who are suffering, their loved ones, and often numerous others connected to the individual.

Sadly, it is often due to this stigma that those in need of treatment do not seek medical attention.

Stigmatizing Language

Often we use stigmatizing terms every day, not realizing the extent of their negative impact. In order to collectively work to humanize the issue of substance use disorders, the following terminology must be avoided when either discussing or writing about this issue.

Think about the negative sentiment attached to each of the following statements:

"My friend is a *drug addict*"

"No matter what we do, she can't seem to get *clean*"

"Our community has a serious *drug abuse* problem"

"He can't seem to avoid *relapse*"

Stigmatizing vs. Affirming

Stigmatizing Language

Affirming Language

Abuser, Addict, Alcoholic

"Clean"

"Dirty"

Drug Abuse

Relapse

Substance Abuse or Misuse

Drug

Lapse

Opioid Replacement Therapy

Stigmatizing vs. Affirming

Stigmatizing Language

Abuser, Addict, Alcoholic

"Clean"

"Dirty"

Drug Abuse

Relapse

Substance Abuse or Misuse

Drug

Lapse

Opioid Replacement Therapy

Affirming Language

A person suffering from a substance use disorder

A person in recovery

A person not yet in recovery

Substance Use

Recurrence

Substance Use

Medication OR non-medically used psychoactive substances

Resume OR Experience a recurrence

Medications for addiction treatment

Talking to Patients about MAT

The Essentials

- ► MAT is standard of care for opioid use disorder
- ► Three FDA-approved medications
- Shared decision-making using motivational interviewing skills

Surgeon General's Report (2016)

- "Well-supported scientific evidence shows that medications can be effective in treating serious substance use disorders, but they are underused."
- "MAT for patients with a chronic opioid use disorder must be delivered for an adequate duration in order to be effective. Patients who receive MAT for fewer than 90 days have not shown improved outcomes."
- "One study suggested that individuals who receive MAT for fewer than 3 years are more likely to relapse than those who are in treatment for 3 or more years."


FACING ADDICTION IN AMERICA

The Surgeon General's Report on Alcohol, Drugs, and Health

Know the Medicines

- ► Buprenorphine
- Methadone
- ► Naltrexone

How Do Opioids Work?



Methadone



Dolophine ® Methadose ®

How does methadone work?

- Methadone binds to the same receptor sites as other opioids
- Suppresses withdrawal and reduces craving
- Oral administration effective
- Slow onset of action
- ► Long duration of action
- Slow offset of action

Why Choose Methadone?

- Accessibility Able to get to an approved program daily
- Pregnant and post-partum women
- ▶ Have severe or chronic pain
- ► People being treated for HIV/AIDS
- ► People who do best with structured programs
- ► Few long-term side effects
- ► Counseling promotes lifestyle changes



































Buprenorphine: The Evidence

- Over 25 years of research on buprenorphine, including over 5,000 patients.
- Clinical trials have established the safety and effectiveness of buprenorphine for the treatment of opioid addiction.
- Effectiveness of buprenorphine has been compared to:
 - ► Placebo (Johnson et al. 1995; Ling et al. 1998; Kakko et al. 2003)
 - Methadone (Johnson et al. 1992; Strain et al. 1994a, 1994b; Ling et al. 1996; Schottenfield et al. 1997; Fischer et al. 1999)
 - ► Methadone and LAAM (Johnson et al. 2000)

Why choose buprenorphine?

- Best treated in doctors' offices
- Pregnant and postpartum women
- ► People being treated for HIV/AIDS
- ► Able to follow a treatment plan
- Motivated to try buprenorphine for MAT



Extended-Release Naltrexone Administration

Amount: one 380mg injection

Method: deep muscle in the buttock

Frequency: every 4 weeks

Must be administered by a healthcare professional and should alternate buttocks each month.

Research on Extended-Release Naltrexone

When compared to placebo, those receiving extended release naltrexone:

- ► Had fewer opioid positive urines
- Stayed in treatment longer
- Had less craving
- Showed greater improvement in the mental component of quality of life and overall health status

Equivalent results to buprenorphine for patients who can tolerate withdrawal

Why choose naltrexone?

- ► Able to stop using for 7-10 days
- Mandated by court or employer
- Comorbid alcohol problems
- ► Motivated to eliminate all opioids now
- ▶ Re-entering from prison or jail


When to choose no medication?

Shared Decision-Making Model

- Associated with better outcomes and patient satisfaction across medical care
- Patient-centered, non-hierarchical and collaborative approach

Decisions in Recovery: Treatment for Opioid Use Disorder

Should I start? Which do I start? How do I start? Recovery tools



Are you finding it difficult to stop using? If you've thought about cutting down or stopping, this site can help. If you are using narcotics, prescription pain medications, heroin, or any other opioid drug, this site has information about some of your treatment options and ways to locate a provider who can help.

You can also watch videos of people who have been where you are. They found a way to succeed in recovery and reclaim their lives. So can you.

Opioid use disorder is a primary, chronic and relapsing disease that affects your body and your brain. Whether this is your first try at overcoming addiction, or a fresh start after many attempts, give yourself credit for having the courage to change.

The site offers a wide variety of resources on recovery, recovery support and treatment. Although recovery and recovery support are related to treatment, they are not the same and you are encouraged to talk with your provider about the treatment options that will work best for you and your unique needs.

https://archive.samhsa.gov/MAT-Decisions-in-Recovery/Default.aspx



TALKING ABOUT MAT

ELLE SCHWAB

SENIOR SUPERVISOR II

RECOVERY SUPPORT SERVICES AND CASE MANAGEMENT



HOW DO WE APPROACH PATIENTS

- What is their drug of choice
- What is their treatment history
- What support do they have (family, friends etc.)
- ▶ What level of treatment are they in (residential, OP, etc.)
- What MAT services have they utilized before
- Did the previous MAT service work for them? Why or why not?
- Are they caught in a "loop" of always the same treatment
- Do they understand the physiological affects of addiction?





INTERVIEWING/ENCOURAGEMENT

- Discuss with the patient the best options for their drug of choice
- What has gotten in the way of their sobriety
- What type of triggers and urges do they have
- If they have repeatedly used the same MAT medication, discuss something different
- Have they had a previous addiction to a MAT medication? Recommend switching up the medication
- Discuss what hasn't worked in the past, why not try something different, it might work this time





Using Motivational Interviewing Skills

What is Motivational Interviewing?

Developed by William Miller (U New Mexico), Stephen Rollnick (Cardiff University School of Medicine), and colleagues over the past three decades. Miller and Rollnick (2012, p. 29) define MI as:

"...designed to strengthen personal motivation for and commitment to a specific goal by eliciting and exploring the person's own reasons for change within an atmosphere of acceptance and compassion."

The Underlying Spirit of MI



MI MicroSkills (the OARS)

Core Skills

- O pen-Ended Questions
- **A** ffirmations
- R eflective Listening
- **S** ummarizing




Open-Ended Questions

- Are difficult to answer with brief replies or simple "yes" or "no" answers.
- Contain an element of surprise; you don't really know what the patient will say.
- Are conversational door-openers that encourage the patient to talk.
- Is this an open-ended or closed-ended guestion?

Types of Reflective Statements

1. Simple Reflection (repeat)





"I'm not sure that I want to take medicines."

Practicing MicroSkills

- Write down something a client might say about his/her opioid use during an intake
- Speaker reads "client" statements
- Others ask open-ended questions and make reflections, simple and complex

Practice Presentation Spoke Development


Spoke Development

Matrix Institute Hub and Spoke System

Spoke Update

Current Spokes	Potential Spokes
 Venice Family Clinic 	AltaMed
 St. John's Well Child and Family Center 	 University Muslim Medical Association (UMMA)
 CLARE Foundation 	 Edelman Westside Mental Health Center

Spoke Development Map



Spoke Development Efforts

- Engaging Agencies and Representatives
 - Coalition meetings
 - ► OUD treatment community meetings
 - Networking
- Potential Spoke Sites: AltaMed and UMMA
 - ► Meetings and setting service objectives

Challenges


- Staffing
 - ► Lack of staff with buprenorphine MAT experience
 - Some spokes are new to addiction treatment
 - Physician engagement in MI and SBIRT at Clinics
 - Scheduling/time constraints
- Community Awareness
 - Misconceptions
 - ▶ Lack of knowledge of HSS Program among other treatment provider
 - Perceptions of addiction patients
- Primary Care Physician Champion
 - ► Enhance mentoring and confidence providing treatment
- Invoicing / Data Submissions
 - Processes are interdependent
 - ▶ One spoke not submitting data stifles invoicing for all spokes

Successes/Lessons Learned

- Physicians enhance communications with other physicians (AltaMed)
 - Understand nuances of primary healthcare settings (e.g. billing, EHRs systems)
 - ► Can lead to provider buy-in
- Outreach initiated from the beginning of grant
 - Increased awareness among service providers and OUD population

Leverage Medical Professionals Peer Support and Mentoring

- Learning Collaborative/MAT Advisory Group
- Seasoned MDs attend and support newly waivered prescribers
- Ongoing contact with peer mentors



Leverage Medical Professionals MD's consult and connect

- Medical Director initiates conversations with potential primary care spokes
- Bring experienced primary care provider to the table for spoke development meetings
- Available to answer questions about how MAT works in a busy clinic setting

Local Newsletter

- ► Information, resources and access
- Reinforcing mechanism to know there are ongoing resources





Central Coast Recovery Options

Vol 2. November/December 2017

A COMMUNICATIONS UPDATE FROM THE CENTRAL COAST RECOVERY OPTIONS

Introducing Robin Oakey, MFT, Project Coordinator for the Central Coast Recovery Options program!

Robin Oakey, MFT, has been an addiction treatment specialist for nearly a decade, working in direct patient care with Vivitrol, Suboxone, and Methadone patients in a variety of clinic settings. resources, and deliver continued training and support to make a difference in successfully addressing the opioid problems in Santa Cruz County.

The MAT Advisory Group

The MAT Advisory Group (A learning collaborative) is a peer mentoring resource and support group of other hunrengrphine prescribers and clinicians

Community Forums

- Involve the community to create a leveraged interest in participation
- ▶ Panels include treatment providers from different settings, law enforcement, local lawmakers and stakeholders
- ► Patients in recovery provide insight into the different faces of substance use disorder



Activity

- Discuss your progress in each of the practice areas
 - ► Learning collaborative and peer support
 - ► Physician involvement in spoke development
 - ► CME presentations
 - Newsletter
 - ► Community Forums
 - Other areas of progress
- What are your successes?
- Where will you put more effort?

QI & PERFORMANCE MEASURES



Skunk Hollow Treatment Center

Nowheresville, CA Sample QI Presentation

Hub Team

- Cindy Brown, Executive Director
- John Smith, H&SS Project Coordinator
- Valeria Vegas, H&SS Nurse Manager
- Dr. Ted Seuss, H&SS Medical Director
- Brian Do, CADC




Spoke Partners


- Sunnyvale Treatment Center (Sunnyvale, CA)
- Redwood City Clinic (Redwood City, CA)
- Santa Clara Wellness Center (Santa Clara, CA)
- Family Health Center (San Mateo, CA)

QI Measure #1: Medication (Hub)






QI Measure #2: Retention (Hub)



Ol Measure #2: Retention (Spokes)






Sample QI Presentation

Ol Measure #3: Hub-to-Spoke Linkage


Hub-to-Spoke Linkage: Sunnyvale Treatment Center



Sample QI Presentation


Ol Measure #4: Spoke-to-Hub Linkage

Spoke-to-Hub Linkage: Sunnyvale Treatment Center



Sample QI Presentation

QI Measure #5: X-Waivered Prescribers



PDSA Report

What improvement is your team trying to make?

PLAN:	DO:
STUDY:	ACT:

SITE DATA REMOVED FOR DISTRIBUTION PURPOSES

NEXT STEPS

- Next quarterly LC session
 - ► May/June 2018 via Zoom Meeting
- Cases for ECHO Clinics
 - Fourth Monday of the month through November
- ►MERF Scholars Program
 - ► Identify providers to apply
- ► Waiver trainings what are your needs?

Gloria Miele, Ph.D.

Learning Collaborative Coordinator

310-267-5888

gmiele@mednet.ucla.edu

Join the CAHSS ListServ

► Email Patrick (pflippinweston@mednet.ucla.edu) to join!

MARK McGOVERN

PROFESSOR AND

DIRECTOR, CENTER FOR HEALTH SERVICES AND IMPLEMENTATION RESEARCH

DIVISION OF PUBLIC MENTAL HEALTH AND POPULATION SCIENCES, DEPARTMENT OF PSYCHIATRY

MEDICAL DIRECTOR OF INTEGRATED BEHAVIORAL HEALTH

DIVISION OF PRIMARY CARE AND POPULATION HEALTH, DEPARTMENT OF MEDICINE

STANFORD UNIVERSITY SCHOOL OF MEDICINE

1520 PAGE MILL ROAD, SUITE 158

PALO ALTO, CALIFORNIA 94304

mpmcg@Stanford.edu